Internationale Publikationen
Hier stellen wir eine Auswahl wissenschaftlicher Veröffentlichungen zur Verfügung, die im Zusammenhang mit der IOZK-Immuntherapie stehen.
Sie können mit Hilfe der Filter eine Auswahl nach Tumorarten und Methoden treffen, oder Suchbegriffe eingeben.
Potentiating prostate cancer immunotherapy with oncolytic viruses
Myeloid and plasmacytoid dendritic cell vaccinations for castration-resistant prostate cancer patients.
Efficacy of intracellular immune checkpoint-silenced DC vaccine
Poly(I:C) enhanced anti-cervical cancer immunities induced by dendritic cells-derived exosomes
Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment
Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy
Radiation and Anti-Cancer Vaccines: A Winning Combination
Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8 T cell activation in the presence of adjuvant temozolomide
Autologous tumor lysate-pulsed dendritic cell vaccination therapy after resection of stage IIA (T2N0, T3N0) esophageal cancer: An analysis of immunological responses.
A prospective, randomized, blinded, placebo-controlled, phase IIb trial of an autologous tumor lysate + yeast cell wall particles (YCWP) + dendritic cells (DC) vaccine vs unloaded YCWP + DC and embedded phase I/IIa trial with tumor lysate particle only (TLPO) vaccine in stage III and stage IV (resected) melanoma to prevent recurrence.
The effect of modulated electro-hyperthermia on temperature and blood flow in human cervical carcinoma
Hyperthermia enhances radiosensitivity of colorectal cancer cells through ROS inducing autophagic cell death
A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer
Newcastle disease virus co-expressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy
EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor immunity in hepatocellular carcinoma cells
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade
Buch Veröffentlichung von Prof. Dr. Schirrmacher: Quo vadis cancer therapy
Modulated electro-hyperthermia induced loco-regional and systemic tumor destruction in colorectal cancer allografts
Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC
Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies